Liminatus Pharma Inc. LIMN
- Market cap
- $5.6M
- P/E
- 0.0×
Follow LIMN
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 30.50 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 1,683.00 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 1 |
Employees
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (4) | (10) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (4) | (10) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (10.13) | (21.50) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (4.15) | (20.97) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | (0.03) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (4.15) | (21.00) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (55.26) | (20.66) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (1) | (10) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (1) | (10) |
FCF
|
|||
| — | — | — | — | — | — | — | — | (19) | (10) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 20 | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | 20 | 1 |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (19) | (10) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (344.72%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | (360.95%) | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 70.02% |
ROE
|
|||
Liminatus Pharma Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CDIO Cardio Diagnostics Holdings, Inc. | $5.7M | 0.0× | Compare |
| ORGS Orgenesis Inc. | $5.7M | 0.0× | Compare |
| NCNA NuCana PLC Sponsored ADR | $5.7M | 0.0× | Compare |
| XBIO Xenetic Biosciences, Inc. | $5.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ERNA Ernexa Therapeutics Inc. | $5.9M | 0.0× | Compare |
| PCSA Heatwurx Inc. | $5.2M | 1.8× | Compare |
| PULM Pulmatrix, Inc. | $6.1M | 0.0× | Compare |
| KAPA Kairos Pharma, Ltd. | $6.1M | 0.0× | Compare |
Liminatus Pharma Inc. (LIMN) key facts
- Liminatus Pharma Inc. (LIMN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, LIMN traded at $4.20, a market capitalization of $5.6 million.
- Return on equity was 70.0% and debt-to-equity 4.80.
Liminatus Pharma Inc. (LIMN) Latest News
24 Aug
Liminatus Pharma Inc. (LIMN) engaged Synex as contract research organization to support phase 1/2a clinical development of CD19xCD22 bivalent CAR-T therapy. Engaging a CRO advances the company's lead CAR-T therapy into early clinical stages, potentially influencing development timelines.
30 Jun
Liminatus Pharma amends definitive merger agreement with InnocsAI to expand oncology cell therapy pipeline. Merger amendment to expand oncology cell therapy pipeline constitutes major strategic move that can significantly alter company trajectory.
21 May
Liminatus Pharma Inc. received a Nasdaq delisting notification. Nasdaq delisting notification directly threatens Liminatus Pharma's exchange listing, liquidity, and capital access.
17 Mar
Liminatus Pharma Inc. (LIMN) announces plans to initiate a Phase 1 clinical trial for IBA101, a next-generation CD47 blocking antibody targeting cancer immunotherapy. Initiating Phase 1 trials for a novel CD47 antibody marks a major pipeline advancement that could boost LIMN's valuation and investor sentiment significantly.
17 Feb
Liminatus Pharma, Inc. priced its $4.0 million public offering. Pricing a $4.0 million public offering provides capital infusion to support operations and pipeline development with moderate impact on financial position and stock performance.
9 Feb
Liminatus Pharma Inc. (LIMN) has been identified as one of the most active stocks in recent trading sessions, reflecting heightened investor interest and trading volume. The company's stock performance is being closely monitored as it navigates market dynamics and potential developments in its operations. Increased trading activity suggests a moderate influence on market sentiment and potential operational aspects.
5 Feb
Liminatus Pharma Inc. (LIMN) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. The company's recent developments and market movements have contributed to its increased visibility among investors. Analysts are closely monitoring LIMN's performance as it navigates current market conditions. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.
4 Feb
Liminatus Pharma Inc. (LIMN) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect recent developments or market sentiment surrounding the company, potentially influencing its stock performance and investor outlook. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
3 Feb
Liminatus Pharma Inc. (LIMN) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect recent developments or market sentiment surrounding the company, potentially influencing its stock performance and investor engagement. Increased trading activity suggests a moderately noticeable influence on market sentiment and investor interest.
30 Oct
Liminatus Pharma Inc. (NASDAQ: LIMN) has signed a Memorandum of Understanding (MOU) with Capital Trust Group for a USD 30 million equity investment. The investment will be structured through an earn-out mechanism and aims to foster future strategic cooperation between the two entities. The equity investment and strategic cooperation are likely to significantly enhance Liminatus Pharma's financial position and market opportunities.
22 Aug
Liminatus Pharma Inc. (LIMN) has been identified as one of the most active stocks in recent trading sessions, indicating heightened investor interest and trading volume. The company's stock performance may reflect broader market trends or specific developments within the firm that are attracting attention from traders and investors alike. Increased trading activity suggests a moderate influence on market sentiment and potential interest in the company's future performance.
25 Jul
Liminatus Pharma Inc. is exploring the creation of a digital asset investment vehicle aimed at raising up to $500 million. This initiative is part of the company's strategy to diversify its capital strategies and enhance its financial position in the evolving digital asset landscape. The formation of a significant investment vehicle could substantially impact Liminatus Pharma's financial strategy and market positioning.
24 Jul
Liminatus Pharma Inc. is advancing its evaluation of a digital asset-linked capital strategy, aiming to leverage blockchain technology to enhance its financial operations and investment opportunities. This initiative is part of the company's broader strategy to innovate and adapt to emerging financial technologies, potentially positioning it favorably in the competitive pharmaceutical landscape. The implementation of a digital asset-linked capital strategy could significantly enhance Liminatus Pharma's financial operations and market positioning.
22 Jul
Liminatus Pharma Inc. has initiated a strategic review of its blockchain-integrated treasury strategy. This move aims to enhance financial operations and leverage blockchain technology for better asset management. The company is exploring innovative approaches to optimize its treasury functions, potentially positioning itself at the forefront of financial technology in the pharmaceutical sector. The strategic review of blockchain integration could significantly enhance financial operations and investor sentiment.